Inclusion Criteria:  Female subjects aged 18 to 75 years old； ECOG performance status 0-1; Life expectancy is not less than 12 weeks; Histological or cytological confirmation of ER+/HER2- recurrent/metastatic breast cancer; Participants with measurable disease must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST1.1; Adequate function of major organs; Voluntary participation in the study, signed informed consent, good compliance and willingness to cooperate with follow-up.  Exclusion Criteria:  Confirmed diagnosis of HER2 positive disease; Participants who previously received SHR6390 or VEGFR inhibitors; Allergy to study drug or its components; Participated in other drug clinical trials within 4 weeks before the first dose; Other malignancies within 3 years, except cured non-melanoma skin cancer , skin basal cell carcinoma and squamous-cell carcinoma or carcinoma in situ of the cervix; Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class > 2), or ventricular arrhythmia which need medical intervention； Tumor has invaded important blood vessels or the tumor is likely to invade important blood vessels and cause fatal hemorrhage during treatment; Urine routine test indicates urine protein ≥(++), or 24-hour urine protein >1.0g; Active HBV/HCV/HIV infection; The investigators determined that other conditions were inappropriate for participation in this clinical trial； Pregnant or breast-feeding women; Central nervous system (CNS) invasion.